Freeze-dried live Mycoplasma gallisepticum (MG) API for oculo-nasal vaccination is converted into a single-dose or multi-dose vial presentation by compounding the active harvest with a cryoprotectant-rich stabilizer before lyophilization. Propagation is performed in Frey’s broth supplemented with 10–15% v/v sterile swine serum; the bulk harvest typically contains 10^7.5–10^8.5 CCU/mL by colour-changing unit enumeration on Frey’s agar. The stabilizer blend is added to reach final concentrations of 5–8% w/v sucrose, 2–4% w/v skim milk solids and 2–3% w/v sorbitol. Filling is carried out under ISO 7 laminar flow into 6R or 10R type I glass vials at 1.0–2.5 mL per vial. Lyophilization uses a freezing ramp to −40 to −50 °C, primary drying at shelf temperature −25 to −15 °C under 0.10–0.20 mbar for 18–36 h, and secondary drying at 20–25 °C until residual moisture is below 3.0% by Karl Fischer titration (USP <921> Method Ia). The terminal product is an off-white porous plug; reconstitution with 20–30 mL sterile diluent produces a suspension for eye drop or nasal drop administration at 20–50 µL per bird. The post-reconstitution titre is maintained at not less than 10^6.0 CCU/dose, with enumeration performed on Frey’s agar under 5–7% CO2 at 37 °C for 7–14 days as described in OIE Terrestrial Manual Chapter 3.3.5. Batch-to-batch variance on production freeze dryers is commonly traced to edge-vial heat transfer; when edge-vial product temperature exceeds −10 °C during primary drying, viable recovery falls by 0.5–1.5 log10 CCU. Storage is at 2–8 °C, and reconstituted product should be used within 2 h; viability loss in hypotonic diluent at 25 °C can exceed 0.5 log10 per 3 h.

What Waterline Variables Reduce Live MG Recovery During Mass Oral Administration?

Water-dispersible powder and granule formats are used only where the strain label permits drinking-water administration; some live MG products are restricted to oculo-nasal or coarse spray routes. For mass oral administration, water-dispersible granules containing live MG API are produced by low-shear blending of lyophilized active bulk with skim milk powder, lactose or mannitol, and buffering salts. The water pH must be held at 6.0–7.2; values below 5.5 reduce viable recovery by more than 1.0 log10 CCU within 30 min. Free chlorine and chloramine are quenched before vaccine addition with sodium thiosulfate at 1.0–2.0 g per 100 L of water or by standing 24 h with aeration. Total hardness above 300 mg/L CaCO3, iron above 0.3 mg/L and zinc above 0.2 mg/L are incompatible because divalent cations destabilize the Mycoplasma membrane; if such water is unavoidable, citric acid 0.5–1.0 g/L is added as a chelator. The powder is suspended in a separate 316L stainless steel or polypropylene pre-dilution tank at 10–20 L per 1000 birds and metered into the drinking line by a proportioner pump at 1:50–1:128. Maximum water contact time is 2 h; after 4 h at 25 °C the residual viable count may drop below the licensed dose. Fluidized-bed granulation is conducted with inlet air at 30–35 °C and product temperature not exceeding 28 °C; final granule moisture is controlled below 5.0% by Karl Fischer titration. The terminal product is a pale-yellow water-soluble powder or granule in aluminium-laminated sachets, packaged under nitrogen with desiccant to maintain water activity below 0.2. Each delivery line sample should contain not less than 10^6.0 CCU/dose, verified by quantitative culture from the pre-dilution stock and the far end of the drinker line.

Coarse Spray Delivery and Aerosol Viability Thresholds in Poultry House Vaccination

In commercial layer and breeder vaccination, coarse spray remains the standard mass application route for live MG vaccines because it delivers vaccine droplets to the beak, face and eye without individual bird handling. The freeze-dried vial is reconstituted with distilled or deionized water at 0.5–1.0 L per 1000 birds; the spray device uses a nozzle generating 100–300 µm volume median diameter droplets at 2–3 bar pressure. Droplet size below 50 µm increases deep respiratory deposition and post-vaccination reactions, while droplets above 300 µm settle quickly and reduce uniform flock coverage. During spraying the suspension is kept at 4–15 °C in an insulated container, and ventilation fans are temporarily shut down to keep relative humidity above 40–50%. Aerosolization at <30% RH reduces viable recovery by 0.5–1.0 log10 CCU within 10 min because Mycoplasma cells lack a cell wall and are highly susceptible to desiccation. The final spray suspension is typically prepared to deliver 10^6.0–10^6.5 CCU per bird dose. Equipment residues of quaternary ammonium compounds above 50 ppm or chlorinated cleaning agents inactivate the vaccine; tanks and lines are rinsed three times with clean water and left to drain before use. Vaccination crews should not administer anti-mycoplasma antibiotics within 72 h before or after vaccination, as tetracyclines, macrolides and fluoroquinolones suppress vaccine strain replication. The terminal product is a diluted coarse-spray suspension for immediate use; any unused spray solution is discarded after 2 h. Published data for strain-specific aerosol recovery under commercial cabinet conditions are limited; therefore each production batch must be validated for post-spray titre under USDA 9 CFR 113.64.

Live MG API is not formulated into injectable emulsions or oil-adjuvanted bacterins. Mycoplasma species lack a peptidoglycan cell wall and are lysed by hypotonic shock and high-shear emulsification; syringeability studies with mineral oil adjuvants show phase separation and free-antigen loss, but published data for this specific configuration are limited. The injectable Mycoplasma gallisepticum products that exist in commercial poultry medicine are inactivated whole-cell bacterins prepared under USDA 9 CFR 113.337, using formalin or binary ethylenimine inactivation and aluminium hydroxide or oil adjuvants. Live MG API is not licensed for injection under USDA 9 CFR 113.64; subcutaneous or intramuscular injection of live MG into chickens is not a registered route because it can produce local granulomatous reactions and systemic spread without evidence of improved protection. Tablet and capsule formats are also not valid downstream presentations for live MG API. Direct compression forces above 8–12 kN reduce viability by more than 2 log10 CCU in tableting trials, and the acidic proventriculus environment below pH 4.0 inactivates the organism before intestinal exposure. Capsule filling requires water activity below 0.2 and low-humidity environments, which are incompatible with Mycoplasma survival unless the API is lyophilized with a dedicated protectant matrix and enteric-coated, for which published data are limited. Unless a regulatory submission demonstrates safety and efficacy of such an oral solid dosage form with strain-specific stability data, tablets and capsules remain outside the approved application envelope for this API.

When a Premix Is Not a Stable Terminal Format for Live MG API

Feed premix and pelleted feed are not viable terminal formats for live MG API because standard poultry feed conditioning operates at 70–85 °C and pellet mill die friction raises product temperature above 60 °C, causing rapid loss of viable Mycoplasma. A liquid drinking-water premix concentrate is the only premix-like format that can be used without unacceptable titer loss. The concentrated stock is prepared by diluting the freeze-dried plug or water-dispersible powder in a 1:10 to 1:50 ratio with chilled potable water and stabilizer; the vessel is constructed from 316L stainless steel or high-density polypropylene. Galvanized steel is incompatible because zinc ions above 0.2 mg/L inactivate the organism. Agitation is limited to an impeller tip speed below 2 m/s because Mycoplasma cells are susceptible to shear. The stock is then metered through a proportioner into the main drinker line to achieve the final dose of not less than 10^6.0 CCU/dose. The use window for the liquid premix concentrate is 2 h at 20–25 °C; at higher temperatures the holding time is shortened to 1 h. Birds must not receive anti-mycoplasma antibiotics in water or feed within 72 h before and after vaccination. The terminal product is a cold, dilute liquid premix for drinking water, not a dry feed premix or pelleted feed product.